Summary
The AI response makes multiple claims about non-FDA (EU/Europe) availability, regulatory marketing authorization, import channels, counterfeit risk, and market exclusivity. The provided FDA cyclobenzaprine hydrochloride extended-release label text does not contain or support these Europe/market-availability, counterfeit, or import-related statements, so alignment with the provided FDA prescribing information is not supported.
Category Scores
Accurate Statements
Cyclobenzaprine is a muscle relaxant.
Not supported/verified by the provided FDA label excerpts (Indications and Usage text is about relief of muscle spasm but does not use the term 'muscle relaxant').
Unsupported Statements
Cyclobenzaprine is widely used in the United States.
The provided FDA prescribing information text does not address US usage frequency.
Cyclobenzaprine is not marketed across Europe under the same product or brand approvals.
The provided FDA label excerpts do not address European marketing/brand approvals or cross-regional availability.
A common reason medicines are absent from many European markets is that they never received or did not maintain marketing authorization in the EU/EEA.
Not addressed in the provided FDA label excerpts.
No company is currently selling cyclobenzaprine in Europe with an active approved dossier for European use.
Not addressed in the provided FDA label excerpts.
If a medicine is not available in Europe, it is usually because regulators have not authorized it for EU/EEA sale or it was withdrawn, rather than because every country has a blanket ban on the ingredient itself.
Not addressed in the provided FDA label excerpts.
Without an approved EU/EEA marketing authorization, routine prescribing and pharmacy dispensing generally cannot happen through normal channels.
Not addressed in the provided FDA label excerpts.
An active ingredient described as 'not available in Europe' may still appear in limited form in certain countries via different brand names, different formulations, or approvals that exist only in parts of the region.
Not addressed in the provided FDA label excerpts.
In Europe, a medicine must be authorized by the relevant regulatory framework to be sold through normal channels.
Not addressed in the provided FDA label excerpts.
Authorization requires the manufacturer to submit efficacy and safety evidence and maintain required documentation for continued authorization.
Not addressed in the provided FDA label excerpts.
If the company that developed or owned the product does not pursue authorization for Europe or stops supporting it, the medicine may never reach European pharmacies.
Not addressed in the provided FDA label excerpts.
Some patients look for cyclobenzaprine through personal import or non-standard channels when it is not available locally.
Not addressed in the provided FDA label excerpts.
Imported or non-standard cyclobenzaprine products may be counterfeit.
Not addressed in the provided FDA label excerpts.
Imported or non-standard cyclobenzaprine products may be mis-dosed.
Not addressed in the provided FDA label excerpts.
Imported or non-standard cyclobenzaprine products may not be equivalent to the approved formulation expected in the origin country.
Not addressed in the provided FDA label excerpts.
When cyclobenzaprine is not available, clinicians typically prescribe other centrally acting muscle relaxants that are authorized in the relevant country.
Not addressed in the provided FDA label excerpts.
Availability can be influenced by market exclusivity, company decisions, or whether the product was withdrawn after authorization changes.
Not addressed in the provided FDA label excerpts.
Patent status can affect who can sell a drug.
Not addressed in the provided FDA label excerpts.
Contradictions
Low
AI Statement
Cyclobenzaprine is widely used in the United States.
Label Reference
Not evaluated/contradicted by the provided FDA label excerpts.
Important Omissions
No FDA-label-relevant dosing, contraindications, boxed warnings, warnings/precautions, adverse reactions, or monitoring statements were included in the AI response, despite the prompt being assessable against the FDA prescribing information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided FDA label excerpts do not support the Europe/availability/import/counterfeit/mis-dosing claims; these statements are informationally unsupported rather than directly derived from FDA labeling. The label does not address these aspects, so the safety impact relative to FDA labeling cannot be validated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims concern EU/EEA availability and import/counterfeit risks, which are absent from the provided FDA prescribing information.
Suggested Improvement
Limit claims to FDA-label-supported information from the provided label sections (e.g., indication as adjunct to rest/physical therapy for acute muscle spasm, short-term use limitation, and labeled dosing guidance). Avoid unsupported assertions about European marketing, regulatory processes, patient import behavior, counterfeit likelihood, or dosing equivalence.